Interruption of macrophage-derived IL-27(p28) production by IL-10 during sepsis requires STAT3 but not SOCS3

Markus Bosmann1, Norman F Russkamp2, Birgit Strobl3

  • 1Center for Thrombosis and Hemostasis, University Medical Center Mainz, 55131 Mainz, Germany; Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, 55131 Mainz, Germany; markus.bosmann@unimedizin-mainz.de.

Insights

Interleukin-10 (IL-10) suppresses the release of Interleukin-27 (IL-27) during sepsis. This finding offers a potential therapeutic target for managing sepsis-induced inflammation and improving patient outcomes.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pathophysiology

Background:

  • Severe sepsis and septic shock are major global health threats, driven by infection-associated inflammation.
  • The role of Interleukin-27 (IL-27) in sepsis is recognized, but its precise regulation remains unclear.
  • Understanding IL-27's molecular control is crucial for developing targeted sepsis therapies.

Purpose of the Study:

  • To investigate the regulatory mechanisms controlling the expression and release of IL-27(p28) during sepsis.
  • To elucidate the role of Interleukin-10 (IL-10) in modulating IL-27 production in sepsis models.
  • To identify potential therapeutic strategies targeting IL-27 in sepsis.

Main Methods:

  • Utilized mouse models of endotoxic shock and polymicrobial sepsis (cecal ligation and puncture).
  • Employed neutralizing antibodies against IL-27(p28) and genetic manipulation (gene deletion of STAT3, SOCS3, IL-10).
  • Analyzed macrophage activation, cytokine release, bacterial burden, and survival rates.

Main Results:

  • Neutralizing IL-27(p28) improved survival, reduced cytokine release, and decreased bacterial load in septic mice.
  • IL-10 significantly inhibited TLR4-induced IL-27(p28) release from macrophages, acting through STAT3-dependent pathways.
  • Genetic deficiency or blockade of IL-10 led to a marked increase in IL-27(p28) levels during sepsis.

Conclusions:

  • IL-10 is identified as a key negative regulator of IL-27(p28) production in the context of infection-induced inflammation.
  • Targeting the IL-10/IL-27 axis presents a promising avenue for therapeutic intervention in sepsis.
  • Further research into modulating IL-27 release could lead to improved sepsis management.